Codexis (CDXS) Aksje Kurs

Codexis Inc is primarily active in the biotechnology industry.

The main competitors of Codexis Inc in the market include companies such as DSM, Ginkgo Bioworks, and Amyris.

Codexis Inc is a leading protein engineering company based in Redwood City, California. Founded in 2002, Codexis specializes in designing and optimizing enzymes for various industries, including pharmaceuticals, food and beverages, and sustainable chemistry. With a strong focus on biocatalysis, the company utilizes its proprietary CodeEvolver® platform to develop customized enzyme solutions that enhance the manufacturing processes of its clients. Over the years, Codexis has established itself as a key player in the biotech industry, collaborating with global partners and attracting numerous high-profile clients. By leveraging its expertise in directed evolution and protein engineering, Codexis continues to drive innovation and provide sustainable solutions to address complex challenges in different sectors. As a leader in the field, Codexis Inc consistently strives to deliver value and impact through the application of biocatalysis and its cutting-edge enzyme technologies.

Codexis Inc has achieved several significant milestones throughout its history. One notable achievement was the commercialization of its proprietary CodeEvolver® protein engineering platform. This innovation enabled the company to develop and optimize bio-based processes for various industries, including pharmaceuticals, food and beverages, and chemicals. Another milestone was when Codexis partnered with leading companies like Merck, GlaxoSmithKline, and Shell, showcasing its reputation as a trusted collaborator. Additionally, the company's successful initial public offering (IPO) in 2010 marked a major milestone, providing Codexis with the financial resources to further expand its cutting-edge biocatalysis technologies. Overall, Codexis Inc has consistently demonstrated industry leadership and achieved significant progress in advancing sustainable solutions.

Codexis Inc is primarily present in the United States.

Codexis Inc represents a strong commitment to innovation and sustainability in the biotechnology industry. The company's corporate philosophy is centered around delivering transformative solutions for its customers and creating value for its stakeholders. Codexis Inc is dedicated to leveraging its proprietary technologies and expertise to develop and commercialize high-performance enzymes and other bio-based products. By harnessing the power of biocatalysis, the company aims to enable more sustainable manufacturing processes across various sectors. Codexis Inc's steadfast dedication to excellence and its focus on delivering sustainable solutions makes it a prominent player in the biotechnology industry.

14 analytikere vurderer for øyeblikket Codexis-aksjen: 11 anbefaler kjøp, 3 hold og 0 salg. For 2026 forventer analytikere at Codexis genererer omsetning på 73,88 M USD og resultat per aksje på −0,37 USD.

Codexis Analytikers kursmål 2026

Omregnet til gjeldende valutakurs handles Codexis-aksjen til 0,94 EUR (1,05 USD).

Codexis-aksjen (CDXS) er notert på 7 børser, blant annet: NASDAQ (CDXS), London (0I0X.L), SIX (Zürich) (4QK.SW), Frankfurt (4QK.F), München (4QK.MU), Düsseldorf (4QK.DU).

Codexis Inc. is a specialist in enzyme technology, operating since 2002 and based in Redwood City, California. The company's business model includes three main areas: enzyme development, proteins, and research services. By combining its capabilities in enzyme technology and protein engineering, Codexis has created unique solutions tailored to the needs of the biotechnology, chemical, pharmaceutical, and food industries. The core business of Codexis is enzyme development. Codexis manufactures enzymes that help customers improve chemical processes by exhibiting higher activities and selectivities, making the production of chemicals and bioproducts more cost-effective and environmentally friendly. The company has developed a range of enzymes used in industrial biotechnology, including medicines, seed treatments, food and feed additives, as well as detergents and cleaning agents. In addition to enzyme development, Codexis also offers proteins that the company uses for biochemical analysis, diagnostics, and protein production. Another business area of Codexis is the manufacturing of enzymes for use in IVD diagnostics. These enzymes are used in medicine and biotechnology, particularly in clinical diagnostics and quality assurance. Codexis also provides research services based on enzyme and protein engineering solutions. The company's research department specializes in developing high-performance enzymes and proteins that enable a variety of applications. Furthermore, Codexis utilizes its research capabilities to offer contract research services in protein engineering and expression, as well as enzyme screening and optimization. Codexis has also developed fluorescence spectroscopy technology that allows for the real-time measurement of enzyme activity. These advanced enzyme engineering tools are essential for customers looking to optimize their processes and improve cost-effectiveness. In terms of its business model, Codexis generates its revenues primarily through the sale of enzyme products and contract research services. The company also pursues licensing revenue for its technology related to the development and use of enzymes in the industry. The company is committed to maintaining and expanding its competitive position in the field of enzyme and protein engineering technology. Codexis continuously strives to develop promising technologies for its customers and strengthen its research and development in this area. By supporting its customers with its specific, customized solutions and continually investing in research and development, Codexis positions itself as a leading provider of enzyme and protein engineering technologies.

forventet omsetningen for Codexis er 73,88 M USD. Denne verdien er basert på nåværende regnskapstall og gjenspeiler selskapets forretningsutvikling.

forventet gevinsten for Codexis er −33,93 M USD. Nettoresultatet viser selskapets lønnsomhet etter fradrag av alle kostnader.

Pris-til-inntjening-ratioen (P/E) for Codexis er for tiden −2,81. P/E-ratioen sammenligner dagens aksjekurs med inntjening per aksje og hjelper investorer med å vurdere verdisetningen av Codexis-aksjen.

Pris-til-salg-ratioen (P/S) for Codexis er for tiden 1,29. P/S-ratioen sammenligner markedskapitalisering med årlig omsetning og fungerer som en verdisettelsesindiktor for Codexis-aksjen.

Eulerpool Quality Score for Codexis er 5/10.

ISIN for Codexis er US1920051067. ISIN (International Securities Identification Number) er en globalt unik identifikator for verdipapirer.

WKN for Codexis er A0Q2S4. WKN (Wertpapierkennnummer) er et seks-sifret tysk verdipapirnummer.

Tickeren for Codexis er CDXS. Tickersymbolet brukes til å handle Codexis-aksjer på børsen.